Effectiveness of Aspirin in Compare With Heparin Plus Aspirin in Recurrent Pregnancy Loss Treatment
NCT ID: NCT01542411
Last Updated: 2012-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
520 participants
OBSERVATIONAL
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Molecular Weight Heparin and Aspirin in the Treatment of Recurrent Pregnancy Loss: A RCT
NCT00564174
Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages
NCT01635426
Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion
NCT00959621
The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy
NCT01633528
Aspirin for the Prevention of Recurrent Venous Thromboembolism
NCT00222677
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
recurrent pregnancy loss
No interventions assigned to this group
thrombophilia, aspirin
No interventions assigned to this group
heparin
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* women had previous venous or arterial thromboembolism or who were heterozygous or homozygous for mutations for FV Leiden G1691A, prothrombin gene G20210A (FII G20210A), and methyltetrahydrofolate reductase C677T (MTHFR C677T)
Exclusion Criteria
* uterine and cervical anatomical disorders on pelvic ultrasonography or hysteroscopy,
* abnormal ovaries and abnormal endocrine tests.
19 Years
35 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yazd Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tahere Jahaninejad, MSC
Role: PRINCIPAL_INVESTIGATOR
Yazd Shahid Sadoughi Medical Sciences University and Health Services, Yazd, Iran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research and Clinical Centre for Infertility
Yazd, Yazd Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2362
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.